Statements Of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities
Net loss	$ (10,820,655)	$ (5,671,195)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	276,618	223,430
Amortization of intangibles	149,490	224,875
Amortization of deferred finance costs	163,034	166,850
Share-based compensation	822,785	887,087
Gain on debt extinguishment	(5,632,171)
Noncash interest	485,857
Adjustment of warrants	9,685,850	(832,148)
Changes in operating assets and liabilities:
Accounts receivable	1,494,116	(118,168)
Inventories	(872,083)	893,745
Prepaid expenses and other current assets	(81,867)	167,242
Other assets	(11,282)	93,950
Accounts payable	1,018,677	(30,047)
Accrued liabilities	(834,799)	537,375
Deferred revenue	(2,387,250)	(374,441)
Other liabilities	112,610	(409,339)
Net cash used in operating activities	(6,431,070)	(4,240,784)
Cash flows from investing activities
Purchase of equipment		(59,768)
Net cash used in investing activities		(59,768)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)
Proceeds from revolving line of credit	7,650,000
Payments of revolving line of credit	(7,650,000)
Proceeds from (payments of) Healthcare Royalty Partners debt	(13,020,780)	(105,272)
Proceeds from (payments of) issuance of stock, net of issuance costs	23,203,051	753,992
Net cash provided by (used in) financing activities	10,082,271	648,720
Net increase (decrease) in cash and cash equivalents	3,651,201	(3,651,832)
Cash and cash equivalents at beginning of period	5,593,582	7,270,301
Cash and cash equivalents at end of period	$ 9,244,783	$ 3,618,469